- Home
- VIRC vs AGEN Comparison
VIRC vs AGEN Comparison
Compare VIRC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIRC | AGEN |
|---|---|---|
| Founded | 1950 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 126.2M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | VIRC | AGEN |
|---|---|---|
| Price | $6.29 | $2.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 53.9K | ★ 613.6K |
| Earning Date | 12-08-2025 | 03-10-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $201,942,000.00 | $106,829,000.00 |
| Revenue This Year | N/A | $5.19 |
| Revenue Next Year | $7.73 | $68.25 |
| P/E Ratio | $25.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.00 | $1.38 |
| 52 Week High | $12.09 | $7.34 |
Technical Indicators
Market Signals| Indicator | VIRC | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.27 | 40.15 |
| Support Level | $6.00 | $2.76 |
| Resistance Level | $6.56 | $3.15 |
| Average True Range (ATR) | 0.26 | 0.17 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 20.54 | 32.00 |
Price Performance
Historical ComparisonAbout VIRC Virco Manufacturing Corporation
Virco Manufacturing Corp is engaged in designing, production and distributing quality furniture for the commercial and education markets. The company manufactures an assortment of products, including mobile tables, mobile storage equipment, desks, computer furniture, chairs, and activity tables, folding chairs, and folding tables. Its primary furniture lines are constructed of tubular metal legs and frames, combined with wood and plastic tops, plastic seats and backs, upholstered seats and backs, and upholstered rigid polyethylene and polypropylene shells.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).